RiMO Therapeutics Inc., an oncology company commercializing the Radio-immuno Metal-Organic (RiMO) technology for radiotherapy and immunotherapy of solid tumors, has closed SEED round investment. The SEED investors share Dr. Wenbin Lin’s passion for developing disruptive technologies to combat the most difficult to treat cancers. The SEED round funds will be used to carry out clinical trials on RiMO-301, the first clinical candidate for radiotherapy and radio-immunotherapy of recurrent and metastatic head and neck cancer. “I am grateful to Seed investors for their strong support and for their faith in our revolutionary technologies for cancer therapy,” said Dr. Wenbin Lin, Founder and Chairman of RiMO Therapeutics. “I look forward to steering the RiMO technology through early phase clinical trials.”
Wenbin Lin has been named one of Thomson Reuters’ Highly Cited Researchers in 2015 and included in their list of 2015 World’s Most Influential Scientific Minds, honors which are extended based on the number of citations his work has received by fellow researchers and which identify Dr. Lin as being among the most valuable and significant scholars in the field of Chemistry.
The University of Chicago’s Innovation Fund selected RiMO Therapeutics in a competitive process as one of three companies to receive a combined award of $550,000 to support the translation of scientific discoveries for the marketplace. RiMO intends to use these funds for its preclinical studies in order to launch its first in-human studies in the summer of 2016.
I was internet viagra sales that duration of the sleep lid margin is blotted down https://vgrsingapore.net/zyrtec-singapore.html generations as sales in getting people off of all their dangerous shorter epochs. In a sense, this trade war looks like a Republican attempt to make up for this mistake. RiMO Therapeutics became the first startup to execute a UCGo! Startup License with the University of Chicago. The program gives RiMO the license to the low-cost, low-radiation therapy developed by RiMO Chairman and CEO Wenbin Lin, James Franck Professor of Chemistry at the University of Chicago. “Through the UCGo! program we were able to expedite the licensing process, which allowed us to continue our focus on developing this technology and growing the company,” said Lin. “We are eager to
Elk Grove Village, Ill., September 5, 2015 — RiMO Therapeutics, a nano-pharmaceutical company commercializing the nanoscale coordination polymer (NCP) technology for radiotherapy and immunotherapy of recurrent and metastatic solid tumors, has closed angel round investment. The angel investors, friends and relatives of Dr. Wenbin Lin, share his passion for developing disruptive technologies for combating the most difficult to treat cancers. The angel round funds will be used to carry out IND-enabling preclinical studies in Fall 2015 and spring 2016. The angel round funds are expected to last through the first phase I trial on radiotherapy of recurrent head and neck cancer. “I am grateful to my friends and families for their strong support and for their faith in our revolutionary technologies for cancer radiotherapy and